Breaking News

Pfizer Acquires Sirio’s Treerly Health Co.

January 14, 2016

Gains women’s nutritional healthcare brand in China

Pfizer has acquired Sirio Pharma’s wholly-owned subsidiary, Treerly Health Co., a women’s nutritional healthcare brand in China. The Treerly portfolio expands Pfizer Consumer Healthcare’s products in China with OTC dietary supplements. Pfizer’s Caltrate calcium supplements and Centrum multivitamin supplements are among the top three brands in the OTC vitamin and minerals supplement category in China.

Sirio Pharma is a private contract manufacturing company in China that produces dietary supplements and drug products, and is currently a qualified third-party supplier to Pfizer Consumer Healthcare. Sirio will continue to supply the Treerly family of products to Pfizer.

“The acquisition of the Treerly brand and its family of products will enhance the portfolio of dietary supplements we offer to our retail customers in China and will enable us to help more consumers improve their health and well-being,” said Keith Choy, regional president, Asia Pacific, Pfizer Consumer Healthcare. “The addition of the Treerly products will also make it possible to leverage our existing sales and marketing capabilities and be more efficient in launching future innovations for consumers in China.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision